Deciphera Pharmaceuticals

We are excited to announce that Deciphera has entered into an agreement to be acquired by ONO Pharmaceutical for $2.4 billion. Together, we will accelerate our shared vision to deliver innovative new drugs and serve patients around the world. Deciphera’s specialized capabilities in kinase drug discovery, our well-established commercial and sales platforms throughout the United States and Europe, and global clinical development capabilities will enable ONO to build a robust presence in oncology. As part of ONO, we will be positioned to advance our work to bring QINLOCK and potentially vimseltinib to more people, sooner than we could as an independent company. For more details, please view the news release and other important information here: https://lnkd.in/gE69XdJ9

Deciphera is participating in a fireside chat at the Stifel Financial Corp. 2024 Virtual Targeted Oncology Forum today at 11:30 AM ET. View the webcast here: https://lnkd.in/dYZ59Js

Deciphera is presenting preclinical data for DCC-3084 at the American Association for Cancer Research (AACR) Annual Meeting 2024, on Sunday, April 7 in San Diego, CA. #AACR24 

We are pleased to present on the discovery of DCC-3116 at the American Chemical Society (ACS) Spring Meeting 2024 in New Orleans today. Learn more: https://bit.ly/3TrUMOe   #ACSSpring2024

On International Women’s Day, and every day, we celebrate the remarkable achievements of the women at Deciphera, across the industry and worldwide. Thanks to Jama Jameson Pitman, our Chief Development Officer, for her reflections. #IWD2024   #InspireInclusion 

This #RareDiseaseDay and year-round, we recognize that tremendous progress has been made in the fight against #cancer but there is still so much more work to be done, especially for people living with rare diseases like #GIST and #TGCT. Learn more about the Deciphera difference: https://lnkd.in/eBcBEYhM  

This #RareDiseaseDay and year-round, we recognize that tremendous progress has been made in the fight against #cancer but there is still so much more work to be done, especially for people living with rare diseases like #GIST and #TGCT. Learn more about the Deciphera difference: https://lnkd.in/eBcBEYhM  

We look forward to participating in fireside chats at the upcoming Cowen Inc., Leerink Partners and Barclays Healthcare Conferences in March. Read more: https://lnkd.in/eqSd_chg

We are pleased to have an oral presentation at the British Sarcoma Group conference, February 27-28 in Leeds, UK, and will also share encore data from the INSIGHT trial-in-progress and the Vimseltinib phase 1 study in two posters.

This International Day of Women and Girls in Science, we are grateful to recognize the incredible, dedicated work the women at Deciphera do to improve the lives of people living with cancer. #IDWGS #WomenInScience